3rd ASCO-ISSLC Lung Multidisciplinary Cancer Management Course (MCMC)

3rd ASCO-ISSLC Lung Multidisciplinary Cancer Management Course (MCMC) is organized by Indian Society for Study of Lung Cancer (ISSLC) and will be held during Mar 24 - 25, 2018 at Postgraduate Institute of Medical Education and Research, Chandigarh, India.

The target audience for this medical event is MD/MS residents and DM/MCh fellows undergoing training in pathology, pulmonary medicine, thoracic surgery, surgical oncology, medical oncology, radiation oncology and palliative care as well as practitioners in the above-mentioned fields. Basically, this is a 'must attend' and 'not to be missed' course for any health care professional who is involved in the management of patients with lung cancer. This CME Conference has been approved for a maximum of 8 Credit Hours of CME (4 credit hours for each day).

Conference Overview :
Lung cancer is the most common cause of cancer-related death globally and in India. Globally it is estimated that seven patients are diagnosed with lung cancer every two minutes and that three patients die from this disease every minute. Lung cancer is responsible for one in every five cancer-related deaths. Most lung cancer patients present in an advanced stage and one of the reasons for this is late referrals to oncologists. Delays in diagnosis of this disease result from lack of awareness as well as an overlap of clinical and radiological features with other pulmonary disorders.

The highlight of this course, as for the previous two courses would be a focus on multi-disciplinary management of lung cancer and in particular, case discussions by multi-disciplinary tumor boards and molecular tumor boards comprised of the international (ASCO) faculty as well as eminent national faculty (including those from the two collaborating institutes - PGIMER, Chandigarh and Tata Memorial Hospital, Mumbai).

Overview of topics To be Covered :
• Essentials of Radiological and Nuclear Imaging in Lung Cancer
• Essentials of Pathological and Molecular Testing in Lung Cancer
• Current TNM staging system
• Endoscopic and invasive mediastinal staging in lung cancer
• Management of early-stage non-small cell lung cancer (NSCLC) including:
? Pre-operative assessment for fitness
? Principles of surgical resection
? Role of SBRT
• Multimodality management of locally advanced NSCLC including:
? Trimodality vs. bimodality treatment approaches
? Neoadjuvant vs. adjuvant treatment approaches
• Metastatic NSCLC including:
? Biomarker Testing and Precision medicine
? Targeted therapies (EGFR, ALK, ROS1 and beyond) for treatment naive and pretreated patients
? Immunotherapy (PD-1/PD-L1 Immune Check Point Inhibitors) - patient selection, PD- L1 testing controversies and specific issues related to imaging and toxicity
? Chemotherapy regimens - doublets, maintenance, the combination with targeted agents
? Oligoprogression and oligo-metastatic disease
• Small cell lung cancer
• Prognostic factors, comorbidities and elderly patients
• Early integration of palliative care
• Specific interventions for bony and brain metastases
• Guideline Implementation and Adherence in Resource-Constrained Settings

Additional details will be posted as soon as they are available.